Bright Minds Biosciences is focused on developing psychedelics-based drugs to treat various central nervous systems and mental health disorders. The company says it currently has a pipeline of patented serotonin 2A and 2C agonists, or substances that initiate a biological response when combined with a receptor.
Stock Performance
Bright Minds Biosciences News 28 articles
- Bright Minds Biosciences presents at Jefferies Global Healthcare Conference
- Bright Minds expands scientific advisory board to support BMB-101 and new Prader-Willi program
- Bright Minds Biosciences announces upcoming conference presentations
- Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
- Bright Minds is Unaware of Any Material Changes
- Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
- Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
- Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
- Bright Minds Announces Effective Date of Share Consolidation
- Bright Minds Announces Proposed Share Consolidation
- Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
- Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
- Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
- Bright Minds Biosciences Announces Non-Executive Director Appointment
- Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
- Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
- Bright Minds Biosciences Announces Resignation of Board Member
- Bright Minds Biosciences Announces Non-Brokered Private Placement
- Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
- Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
- Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
- Psychedelic Sector News – Weekly Extractions: August 24, 2022
- Bright Minds Announces Overnight Marketed Offering of Units
- Bright Minds Biosciences Comments on Recent Trading Activity
- Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
- Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
- Bright Minds Biosciences Announces Listing on Canadian Stock Exchange
- Fighting Depression with Targeted, Next Generation Psychedelics: A Conversation with Bright Minds CEO Ian McDonald